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Abstract
BACKGROUND: Various studies have shown variations in the interleukin-4 (IL) gene associated with type 2 diabetes 
mellitus (T2DM) in different populations and ethnicities.
AIM: The objective of this study was to determine the genetic variation of the IL-4 −33 C/T gene in some T2DM 
patients compared with healthy control in Medan, Sumatera Utara province, Indonesia.
METHODS: DNA from T2DM patients and healthy control was isolated, then the determination of the IL-4 −33 C/T 
gene polymorphism was carried out using the polymerase chain reaction-restriction fragment length polymorphism 
technique.
RESULTS: In all samples of this study, IL-4 −33 C/T gene polymorphisms were found in patients with T2DM and 
healthy control but were not statistically significant.
CONCLUSION: The IL-4 −33 C/T gene polymorphism has no relationship with the incidence of T2DM in a portion of 
our population in Medan, Sumatera Utara province, Indonesia.
Edited by: Slavica Hristomanova-Mitkovska
Citation: Daulay M, Sari MI. Interleukin-4 −33 C/T Gene 
Polymorphisms are not Associated with Type 2 Diabetes 
Mellitus. Open Access Maced J Med Sci. 2020 Nov 03; 
8(A):1-4. 
https://doi.org/10.3889/oamjms.2020.5419
Keywords: Diabetes; Gene; Interleukin; Polymorphisms; 
Sumatera Utara
*Correspondence: Milahayati Daulay, Department of 
Physiology, Faculty of Medicine, Universitas Sumatera 
Utara, Jl. Dr. Mansur No. 5 Kampus USU Medan, 
Sumatera Utara, Indonesia. 
E-mail: milahayati.daulay@usu.ac.id
Received: 03-Sep-2020
Revised: 11-Oct-2020
Accepted: 22-Oct-2020
Copyright: © 2020 Milahayati Daulay, Mutiara Indah Sari
Funding: This study was supported by a grant from 
TALENTA USU 2018, Indonesia
Competing Interests: The authors have declared that no 
competing interests
Open Access: This is an open-access article distributed 
under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0)
Introduction
Based on various epidemiological studies, 
the prevalence of diabetes mellitus (DM) tends to 
increase. WHO in 1998 estimated the prevalence of 
DM worldwide as much as 300 million by 2025. The 
highest number of DM sufferers is predicted to be 
in the Western Pacific and Southeast Asia regions. 
Increasing the number of people with DM occurs in 
developing countries, mainly [1], [2], [3]. In developing 
countries, as many as 90–95% of all DM sufferers 
are DM type 2 groups [4]. The International Diabetes 
Federation estimates that people with diabetes in 
Indonesia increased from 10 million in 2015 to 16.2 
million in 2040 [5].
DM is a group of metabolic diseases 
characterized by hyperglycemia as a result of a 
disorder in insulin secretion, insulin action, or both [6]. 
Type 2 diabetes is a complex disorder resulting from 
the interaction of genetic and environmental factors. 
Genetic identification in people with DM is essential 
to understand the pathogenesis of DM [7], [8]. Many 
kinds of research show that the inflammatory process 
plays a role in the incidence and complications of 
type 2 diabetes [1], [9]. Chronic hyperglycemia can 
increase the production of pro-inflammatory and anti-
inflammatory cytokines. One of the anti-inflammatory 
cytokines that play a role in type 2 diabetes is 
interleukin (IL)-4 [10]. Several studies have shown an 
association between IL-4 gene polymorphisms and 
the incidence of DM and its complications in different 
populations and ethnicities. This study aimed to 
evaluate the polymorphism of the IL-4 −33 C/T gene 
in type 2 DM (T2DM) patients compared with healthy 
control in our subset of resident in Medan, Sumatera 
Utara, Indonesia. The study is the first one to analyze 
the polymorphism of the IL-4 gene at this locus in 
people with T2DM.
Methods
The study is analytical research with a cross-
sectional study approach. The participants of the study 
were patients with T2DM who underwent outpatient care 
at Universitas Sumatera Utara Hospital and healthy 
control taken from the same place. The sampling 
technique used was purposive sampling. The number 
of research subjects was 81 subjects consisting of 40 
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subjects with T2DM and 40 healthy control subjects. 
The ethics of this study was approved by the Health 
Research Ethics Committee of the Faculty of Medicine, 
Universitas Sumatera Utara. The research subjects 
signed the consent form after being given a detailed 
explanation and understanding of the purposes and 
benefits of the study before the research procedure. 
All participants’ blood was drawn for DNA isolation, 
followed by gene analysis using the polymerase chain 
reaction-restriction fragment length polymorphism 
(PCR-RFLP) method.
Examination of IL-4 −33 C/T gene 
polymorphisms
DNA isolation was carried out using the 
Wizard® Genomic DNA Purification Kit (Promega, 
USA). The IL-4 −33 C/T gene PCR procedure refers to 
the technique used in the study of Micheal et al. [11]. 
The primers used, PCR products, restriction enzymes, 
and RFLP fragments can be seen in Table 1.
Table 1: Primer used for genotyping and genomic sequence 
polymorphism analysis of IL-4−33 C/T gene by RFLP
Primer Primer sequence PCR 
product
Restriction 
enzyme
RFLP 
fragments
rs2070874_ F
rs2070874_R
CAAGTTACTGACAATCTGGTGT
CGGCACATGCTAGCAGGAA
223 bp BsmAI C = 178, 45
T = 140, 
45, 38
IL-4: Interleukin 4; RFLP: Restriction fragment length polymorphism; PCR: Polymerase chain reaction; 
bp: Base pairs
The PCR composition contains 1× Taq 
Buffer, 10 pmol primer forward, 10 pmol primers 
reverse, 0.2 mM dNTP, 1U Taq DNA polymerase, and 
100 ng genomic DNA. PCR amplification used initial 
denaturation at 95°C for 5 min. Subsequent PCR 
examinations were carried out for 35 cycles in the 
form of denaturation (95°C for 45 s), annealing (58°C 
for 45 s), extensification (72°C for 45 s), and final 
extensification (72°C for 7 min). Cutting PCR products 
is done by giving BsmAI restriction enzymes. The cut 
results were examined using electrophoresis with 4% 
agarose.
Statistical analysis
Data were analyzed using statistical software. 
This study uses the Kolmogorov–Smirnov normality 
test to determine the normality of data distribution 
analytically. The Mann–Whitney test tested differences 
in gene polymorphisms between groups. p < 0.05 were 
considered statistically significant.
Results
Analysis of the IL-4 −33 C/T gene polymorphism 
can be seen in Table 2, which is found in 3 alleles, CC, 
CT, and TT genotypes.
The frequency of the CC genotype was 4 
(10.0%) in the T2DM patients and 2 (4.9%) in the healthy 
control. Our results also revealed that the frequency 
of the CT genotype was 16 (40.0%) and 17 (41.5%) 
in the patients and healthy control, respectively. The 
frequency of the TT genotype was 20 (50.0%) in the 
patients and 22 (53.7%) in the healthy control. A non-
significant difference between the two groups regarding 
genotypes was confirmed (p > 0.05).
Discussion
IL-4 is an anti-inflammatory cytokine that 
plays a role in immune system regulation. Studies 
show that IL-4 plays a role in autoimmune and allergic 
diseases such as multiple sclerosis, systemic lupus 
erythematosus, nephrotic syndrome, graft rejection, 
asthma, and DM types 1 and 2. Immunologists say that 
IL-4 gene polymorphisms are associated with various 
immune system disorders, such as polymorphisms in 
the IL-4 promoter region (IL4 −590 C/T) associated 
with atopic dermatitis, multiple sclerosis, rheumatoid 
arthritis, and atopic asthma [12], [13]. The inflammatory 
process that is mediated by the immune system is a 
pathophysiological mechanism seen in diabetes and 
its complications [14]. DM is a complex metabolic 
disorder resulting from the interaction of genetic and 
environmental factors. Chronic hyperglycemia causes 
inflammation that is characterized by increased cytokine 
production. IL-4 is one of the anti-inflammatory cytokines 
associated with T2DM. IL-4 is a cytokine produced by T 
lymphocyte cells which have a role in the activation of 
B cells to form antibodies [15], [16]. Several regions on 
chromosomes containing DM-related genes have been 
identified and several genes have been recognized for 
their role [17].
This study generally aims to explain the 
description of genetic polymorphism as a risk factor 
for T2DM. In this study, there was an IL-4 −33 C/T 
gene polymorphism in patients with T2DM and 
healthy control, but the difference was not significant. 
Our findings are the first study to examine the 
polymorphism of the IL-4 gene at this locus. Previous 
studies examined the IL-4 gene polymorphism at 
different loci with different results. Research conducted 
by Arababadi in Iran found no significant differences in 
the polymorphism of the IL-4 gene in the −590 region in 
Table 2: Characteristics of type 2 diabetic patient and healthy 
control
Characteristics Control (n = 41) T2DM (n = 40) p
Sex
Male 20 (48.7%) 21 (52.5%)
Female 21 (51.3%) 19 (47.5%)
Age (years) 46.83 ± 11.7 58.73 ± 10.8
Gene polymorphisms
CC 2 (4.9%) 4 (10.0%) >0.05
CT 17 (41.5%) 16 (40.0%)
TT 22 (53.7%) 20 (50.0%)
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people with T2DM compared with healthy control [18]. 
Završnik also found no significant difference in the IL-4 
−590 C/T gene polymorphism in T2DM patients with 
nephropathy in Slovenia [19]. However, in Egypt, Alsaid 
found a significant difference in the IL-4 −590 C/T gene 
polymorphisms between T2DM patients compared 
with healthy control [20]. This shows that the IL-4 
−590 C/T gene polymorphism is a risk factor for T2DM 
in the population in Egypt. The same thing was also 
found in the study of Arababadi in Iran. In this study, 
there were significant differences between C/C, T/C, 
and T/T genotypes in T2DM patients with nephropathy 
compared to healthy control [21]. This means that 
functionally, the IL-4 gene polymorphism plays an 
important role in the pathogenesis of complications 
of diabetic nephropathy in T2DM patients. In line with 
the research previously mentioned, another study 
found a significant difference in the IL-4 −590 C/T gene 
polymorphisms in T2DM patients with chronic kidney 
disease compared with those without chronic kidney 
disease and healthy subjects in India [2]. Meanwhile, in 
Taiwan, polymorphism of the IL-4 −589 C/T and −34 C/T 
genotypes differed significantly between T2DM patients 
and control subjects [22]. The differences in these 
studies indicate that unique genetic characteristics and 
possibly different etiological or environmental factors 
may be involved in the pathogenesis of T2DM.
In general, we did not find an association between 
IL-4 −33 C/T gene polymorphisms in T2DM patients, in 
Medan, Sumatera Utara, Indonesia. This denotes that 
IL-4 may not be a risk factor for T2DM patients in this 
population. However, taking into account the limitations of 
the study, particularly related to the relatively small sample 
size, we suggest a wider study with a higher number 
of cases and controls. Further research in different 
communities in Indonesia can strengthen the results of 
this study. We also recommend more extensive research 
by analyzing blood levels of cytokines and considering 
diabetes complications that occur in T2DM patients.
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